Cardiff Oncology, Inc.CRDFEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
CRDF Q4 FY2025 Key Financial Metrics
Revenue
$243.0K
Gross Profit
N/A
Operating Profit
$-7.8M
Net Profit
$-7.2M
Gross Margin
N/A
Operating Margin
-3221.0%
Net Margin
-2969.5%
YoY Growth
62.0%
EPS
$-0.11
Cardiff Oncology, Inc. Q4 FY2025 Financial Summary
Cardiff Oncology, Inc. reported revenue of $243.0K (up 62.0% YoY) for Q4 FY2025, with a net profit of $-7.2M (up 38.8% YoY) (-2969.5% margin).
Key Financial Metrics
| Total Revenue | $243.0K |
|---|---|
| Net Profit | $-7.2M |
| Gross Margin | N/A |
| Operating Margin | -3221.0% |
| Report Period | Q4 FY2025 |
Cardiff Oncology, Inc. Annual Revenue by Year
Cardiff Oncology, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $593.0K).
Cardiff Oncology, Inc. Quarterly Revenue & Net Profit History
Cardiff Oncology, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $243.0K | +62.0% | $-7.2M | -2969.5% |
| Q3 FY2025 | $120.0K | -27.3% | $-11.3M | -9381.7% |
| Q2 FY2025 | $121.0K | -25.8% | $-13.9M | -11523.1% |
| Q1 FY2025 | $109.0K | -46.8% | $-13.4M | -12324.8% |
| Q4 FY2024 | $150.0K | -3.8% | $-11.8M | -7858.0% |
| Q3 FY2024 | $165.0K | +17.0% | $-11.9M | -7184.8% |
| Q2 FY2024 | $163.0K | +50.9% | $-11.8M | -7225.8% |
| Q1 FY2024 | $205.0K | +147.0% | $-10.0M | -4883.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $205000 | $163000 | $165000 | $150000 | $109000 | $121000 | $120000 | $243000 |
| YoY Growth | 147.0% | 50.9% | 17.0% | -3.8% | -46.8% | -25.8% | -27.3% | 62.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $74.0M | $66.1M | $62.9M | $97.2M | $84.8M | $75.7M | $63.8M | $61.9M |
| Liabilities | $13.1M | $13.7M | $13.5M | $14.2M | $13.9M | $17.1M | $15.0M | $16.5M |
| Equity | $60.9M | $52.4M | $49.4M | $82.9M | $70.9M | $58.6M | $48.8M | $45.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.7M | $-9.2M | $-10.5M | $-10.3M | $-12.8M | $-8.3M | $-10.8M | $-6.0M |